Business
Medicare provider number
Medicare provider number.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n RNS Number : 3212I\n Renalytix AI PLC\n 01 April 2020\n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n (\"RenalytixAI\", the \"Company\")\n \n \n \n \n \n Noridian Healthcare Solutions qualifies RenalytixAI as provider for services\n \n \n \n \n \n Qualification an important milestone towards Medicare Coverage determination \n \n \n \n \n \n Renalytix AI plc \n (LSE\n : RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces\n that it has been granted a Medicare provider number for the Company's Salt Lake City Utah clinical laboratory.\n \n \n \n \n \n The Company's application for a Medicare Provider Transaction Access Number (\"PTAN\") was reviewed by Noridian Healthcare Solutions, the regional Medicare Administrative Contractor (\"MAC\") with responsibility for overseeing facilities and providers located in the western United States. RenalytixAI is now qualified as a provider and can bill for services provided to patients with Medicare and Medicaid health insurance coverage in the United States.\n \n \n \n \n \n The Company estimates that Medicare and Medicaid insurance programmes cover between 50% - 60% of patients likely to benefit from KidneyIntelX™ testing.\n \n \n \n \n \n Receiving a Medicare PTAN is an important milestone toward obtaining a Medicare coverage determination for KidneyIntelX™. The Company is immediately initiating efforts to secure a Local Coverage Determination through the Molecular Diagnostic Services (MolDX) Program. MolDX was developed by Palmetto GBA, another MAC, in 2011 to identify and establish coverage and reimbursement for molecular diagnostic tests. This programme performs the following functions for MACs by:\n \n \n \n \n \n · \n Facilitating detailed and unique identification through registration of molecular diagnostic tests to facilitate claims processing and to track utilization;\n \n \n · \n Establishing clinical utility expectations;\n \n \n · \n Completing technical assessments of published test data to determine clinical utility and coverage; and\n \n \n · \n Establishing reimbursement.\n \n \n \n \n \n When issued the local coverage determination will mean that the Salt Lake City laboratory can be reimbursed for KidneyIntelX™ testing ...